Presentation is loading. Please wait.

Presentation is loading. Please wait.

Peripheral T-Cell Lymphoma in 2013

Published byEarl Summers Modified over 6 years ago

Similar presentations

Presentation on theme: "Peripheral T-Cell Lymphoma in 2013"— Presentation transcript:

1 Peripheral T-Cell Lymphoma in 2013

2 Program Goal

3 WHO 2008 Classification of Mature T/NK-Cell Neoplasms

4 Use of the Term PTCL

5 PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas

6 International PTCL Study: Major NHL Types by Region

7 Key Points in the Pathology Characteristics of the Most Common Subtypes of PTCL

8 ALK and ALCL

9 Outcomes by PTCL Subtypes

10 Prognostic Indices for PTCL

11 Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Results of a Prospective Multicenter Study

12 CHOP: First-line Treatment of PTCL

13 Alemtuzumab (A) + Chemotherapy First-line treatment of PTCL

14 CHOP+ and Non-CHOP: First-line Treatment of PTCL

15 Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-Free Survival of Younger Patients

16 Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-free Survival of Younger Patients (cont)

17 Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Survival

18 Prognostic Factors in Trials of ASCT in First Remission

19 ICE and Planned ASCT for Relapsed/ Refractory T-Cell Lymphoma: PFS From ICE

20 CIBMTR Auto and Allo for PTCL: Outcomes Excluding Patients in CR1

21 Retrospective Analyses of Allogeneic Stem-Cell Transplantation for PTCL

22 Approved Agents in Relapsed/Refractory PTCL

23 PROPEL: Adverse Events ≥ Gr 3 Occurring in ≥ 3% of Patients (n = 111)

24 Treatment-related Adverse Events With Romidepsin in ≥ 20% of Patients (N = 131)

25 Brentuximab Vedotin: Phase 2 Study in Relapsed/Refractory Systemic ALCL

26 Brentuximab Vedotin in Relapsed ALCL: Toxicities

27 Brentuximab: Best Clinical Response by Disease Diagnosis

28 Brentuximab: Maximum Tumor Volume Reduction by Frequency of CD30+ Cells

29 Front-line Therapy: Study Design (Combination Therapy Arms)

30 Front-line Therapy: Best Response by Disease Diagnosis

31 Bendamustine in T-Cell Lymphoma (BENTLY Trial)

32 Lenalidomide in Relapsed/Refractory TCL: Phase 2 Trial

33 Belinostat: PTCL Response Assessed by Central Review

34 Belinostat: Response Rate by CPRG Lymphoma Diagnosis

35 Belinostat: Grade ≥3 Nonhematologic AEs in Patients With R/R PTCL (N=120)

36 MLN8237: Response (PR + CR) by Histology

37 IPI-145: A PI3K-δ,γ Inhibitor

38 Early Signs of Clinical Activity of IPI-145 in T-Cell Lymphoma

39 Mogamulizumab (KW-0761) Anti-CCR4 Monoclonal Antibody

40 Recommended Approach to Patients With Relapsed PTCL (NOS, AITL, ALCL)

41 Abbreviations

42 Abbreviations (cont)

43 Abbreviations (cont)

44 Abbreviations (cont)

45 References

46 References (cont)

47 References (cont)

48 References (cont)

49 References (cont)

50 References (cont)

51 References (cont)

Download ppt "Peripheral T-Cell Lymphoma in 2013"

Similar presentations

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas Illidge T et al. Proc ASH 2011;Abstract.

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas Illidge T et al. Proc ASH 2011;Abstract.
Gopal AK et al. Proc ASH 2013;Abstract 4382.

Gopal AK et al. Proc ASH 2013;Abstract 4382.
Moskowitz CH et al. Proc ASH 2014;Abstract 290.

Moskowitz CH et al. Proc ASH 2014;Abstract 290.
1Coiffier B et al. Proc ASH 2010;Abstract 114.

1Coiffier B et al. Proc ASH 2010;Abstract 114.
Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.

Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, :00 PM.
Belinostat, a Novel Pan-Histone Deactylase Inhibitor (HDACi), in Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the BELIEF Trial1 Belinostat.

Belinostat, a Novel Pan-Histone Deactylase Inhibitor (HDACi), in Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the BELIEF Trial1 Belinostat.
LaCasce A et al. Proc ASH 2014;Abstract 293.

LaCasce A et al. Proc ASH 2014;Abstract 293.
ECHELON-2: Phase 3 Trial of Brentuximab Vedotin and CHP versus CHOP in the Frontline Treatment of Patients (Pts) with CD30+ Mature T-Cell Lymphomas (MTCL)1.

ECHELON-2: Phase 3 Trial of Brentuximab Vedotin and CHP versus CHOP in the Frontline Treatment of Patients (Pts) with CD30+ Mature T-Cell Lymphomas (MTCL)1.
Advances in the treatment of T cell lymphomas Yok-Lam Kwong Department of Medicine Queen Mary Hospital.

Advances in the treatment of T cell lymphomas Yok-Lam Kwong Department of Medicine Queen Mary Hospital.
A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Complete remissions with SGN-35 weekly dosing: a phase 1 dose-escalation study in relapsed/refractory HL or systemic ALCL patients Nancy L Bartlett,

Complete remissions with SGN-35 weekly dosing: a phase 1 dose-escalation study in relapsed/refractory HL or systemic ALCL patients Nancy L Bartlett,
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.

MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy 1 Final.

Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy 1 Final.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
DLBCL with less than PR to second line therapy… Correcting a Misconception…. Koen van Besien, MD Weill Cornell Medical College, NY.

DLBCL with less than PR to second line therapy… Correcting a Misconception…. Koen van Besien, MD Weill Cornell Medical College, NY.
High Response Rates to Crizotinib in Advanced, Chemoresistant ALK+ Lymphoma Patients 1 Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive.

High Response Rates to Crizotinib in Advanced, Chemoresistant ALK+ Lymphoma Patients 1 Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive.
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.
Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma.

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma.

Similar presentations

Ads by Google